MicroRNA‑126 inhibits proliferation and metastasis by targeting pik3r2 in prostate cancer

Song,Lei; Xie,Xubio; Yu,Shaojie; Peng,Fenghua; Peng,Longkai

doi:10.3892/mmr.2015.4661

MicroRNA‑126 inhibits proliferation and metastasis by targeting pik3r2 in prostate cancer

Authors:
- Lei Song
- Xubio Xie
- Shaojie Yu
- Fenghua Peng
- Longkai Peng
View Affiliations

Affiliations: Department of Urological Organ Transplantation, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China
Published online on: December 9, 2015 https://doi.org/10.3892/mmr.2015.4661
Pages: 1204-1210
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The dysregulation of miR‑126 has been reported to correlate with the progression of several cancer types. The present study demonstrated that miR‑126 was significantly downregulated in prostate cancer (PCa) tissues compared with normal prostate tissues. In vitro and in vivo studies indicated that forced overexpression of miR‑126 significantly suppressed the proliferation of PCa cell lines. Additionally, a Transwell assay showed that enhanced expression of miR‑126 inhibited metastasis in PCa in vitro. Furthermore, pik3r2 was confirmed to be a direct target of miR‑126 in PCa. It was also shown that pik3r2 was upregulated in PCa tissues and this inversely correlated with miR‑126 in PCa tissues. In conclusion, these results revealed that aberrant expression of miR‑126 promoted the progression of PCa and may serve as a novel therapeutic biomarker for PCa.

View Figures

View References

1	Yamamoto S, Kawakami S, Yonese J, Fujii Y, Urakami S, Masuda H, Numao N, Ishikawa Y, Kohno A and Fukui I: Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy. Jpn J Clin Oncol. 42:541–547. 2012. View Article : Google Scholar : PubMed/NCBI
2	Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, Wang G, Liu Z and Debré B: A comparative study of prostate cancer detection and management in China and in France. Can J Urol. 16:4472–4477. 2009.PubMed/NCBI
3	Klotz L: Active surveillance for prostate cancer: For whom? J Clin Oncol. 23:8165–8169. 2005. View Article : Google Scholar : PubMed/NCBI
4	Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, Shariat SF, Jeldres C, Graefen M, Bénard F, McCormack M, et al: A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 25:3576–3581. 2007. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
6	Vaiopoulos AG, Athanasoula KCh and Papavassiliou AG: Epigenetic modifications in colorectal cancer: Molecular insights and therapeutic challenges. Biochim Biophys Acta. 1842:971–980. 2014. View Article : Google Scholar : PubMed/NCBI
7	Romero Otero J, Garcia Gomez B, Campos Juanatey F and Touijer KA: Prostate cancer biomarkers: An update. Urol Oncol. 32:252–260. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
9	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
10	Petri A, Lindow M and Kauppinen S: MicroRNA silencing in primates: Towards development of novel therapeutics. Cancer Res. 69:393–395. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yang J, Zhao H, Xin Y and Fan L: MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 115:987–995. 2014. View Article : Google Scholar
12	Nassirpour R, Mehta PP and Yin MJ: miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3. PLoS One. 8:e796552013. View Article : Google Scholar : PubMed/NCBI
13	Ouyang H, Gore J, Deitz S and Korc M: microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene. 33:4664–4674. 2014. View Article : Google Scholar :
14	Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY and Zhuang SM: MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating matrix metal-loproteinase 2 expression. Hepatology. 54:1729–1740. 2011. View Article : Google Scholar : PubMed/NCBI
15	Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, Jiang L, Zhang X, et al: MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6 (STAT6). Biochem Biophys Res Commun. 445:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
16	Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, Lou G, Wang X, Lou F, Yen Y, et al: miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene. 33:4296–4206. 2014. View Article : Google Scholar
17	Huang TH and Chu TY: Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene. 33:3636–3647. 2014. View Article : Google Scholar
18	Li Z, Li N, Wu M, Li X, Luo Z and Wang X: Expression of miR-126 suppresses migration and invasion of colon cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
19	Sun X, Liu Z, Yang Z, Xiao L, Wang F, He Y, Su P, Wang J and Jing B: Association of microRNA-126 expression with clini-copathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy. Diagn Pathol. 8:2082013. View Article : Google Scholar
20	Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S and Zhou L: NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 310:35–45. 2011. View Article : Google Scholar : PubMed/NCBI
21	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
22	Bagchi P, Nandi S, Nayak MK and Chawla-Sarkar M: Molecular mechanism behind rotavirus NSP1-mediated PI3 kinase activation: Interaction between NSP1 and the p85 subunit of PI3 kinase. J Virol. 87:2358–2362. 2013. View Article : Google Scholar :
23	Mulrane L, McGee SF, Gallagher WM and O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res. 73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
24	Cai J, Yang C, Yang Q, Ding H, Jia J, Guo J, Wang J and Wang Z: Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis. 2:e752013. View Article : Google Scholar : PubMed/NCBI
25	Li X, Chen YT, Josson S, Mukhopadhyay NK, Kim J, Freeman MR and Huang WC: MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One. 8:e709872013. View Article : Google Scholar : PubMed/NCBI
26	Tian L, Fang YX, Xue JL and Chen JZ: Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One. 8:e758852013. View Article : Google Scholar : PubMed/NCBI
27	Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, de Vere White RW and Kung HJ: miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 33:2495–2503. 2014. View Article : Google Scholar
28	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
29	Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan WK, Tian T, Qiu YM and Luo HS: Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS One. 8:e812032013. View Article : Google Scholar : PubMed/NCBI
30	de Giorgio A, Castellano L, Krell J and Stebbing J: Crosstalk-induced loss of miR-126 promotes angiogenesis. Oncogene. 33:3634–3635. 2014. View Article : Google Scholar
31	Coutte L, Dreyer C, Sablin MP, Faivre S and Raymond E: PI3K-AKT-mTOR pathway and cancer. Bull Cancer. 99:173–180. 2012.In French.
32	Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
33	Zhang J, Zhang Z, Zhang DY, Zhu J, Zhang T and Wang C: microRNA 126 inhibits the transition of endothelial progenitor cells to mesenchymal cells via the PIK3R2-PI3K/Akt signalling pathway. PLoS One. 8:e832942013. View Article : Google Scholar : PubMed/NCBI
34	Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, Nogueira V, Hahn-Windgassen A, Kiyokawa H and Hay N: Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 10:269–280. 2006. View Article : Google Scholar : PubMed/NCBI
35	Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, et al: Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 10:159–167. 2006. View Article : Google Scholar : PubMed/NCBI